StemBioSys
San Antonio, US · Delaware corporation · 1 known investors
StemBioSys develops cell culture technology, including the patented CELLvo Matrix that replicates the body's physiological microenvironment to expand mesenchymal stem cells and specialty cells while preserving their stem-like properties. It supplies cells and cell expansion tools for stem cell research and regenerative medicine applications.
Founders & leadership
CX
Chen Xiao-DongCo-founder
SD
Steven DavisCo-founder
XC
Xiao-Dong ChenCo-founder
TB
Travis BlockChief Technology Officer
JC
Jean CheeverNamed on SEC filing
MD
Mark D HorseyNamed on SEC filing
RH
Robert HutchensNamed on SEC filing
JW
John W FeikNamed on SEC filing
CB
Catherine BurzikNamed on SEC filing
RS
Robert S LangerNamed on SEC filing
Board
IC
PC
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.5M disclosed across 2 of 4 rounds · 2016–2020
▶$1.5MofferedDec 2020 · BiotechnologyRule 506(b)
▶$1.5MofferedDec 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ian ClementsDirector
- Steven DavisDirector
- Mark HorseyExecutive Officer
- Becky CapDirector
- Xiao-Dong ChenDirector
- Robert HutchensExecutive Officer, Director
- Robert LangerDirector
- John W FeikDirector
- Catherine BurzikDirector
- Jean CheeverDirector
- Paul CastellaDirector
- Offering amount
- $1.5M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KofferedJan 2020 · BiotechnologyRule 506(b)
▶$500KofferedJan 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xiao-Dong ChenDirector
- Steven DavisDirector
- Catherine BurzikDirector
- Mark HorseyExecutive Officer
- Paul CastellaDirector
- Robert LangerDirector
- John FeikDirector
- Ian ClementsDirector
- Jean CheeverDirector
- Robert HutchensExecutive Officer, Director
- Offering amount
- $500K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedJun 2019 · 32 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJun 2019 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ian ClementsDirector
- John W FeikDirector
- Robert HutchensExecutive Officer, Director
- Robert S LangerDirector
- Paul CastellaDirector
- Steven DavisDirector
- Catherine BurzikDirector
- Mark HorseyExecutive Officer
- Jean CheeverDirector
- Xiao-Dong ChenDirector
- Offering amount
- $3M
- Amount sold
- $1.4M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedMay 2018 · 47 investors · BiotechnologyRule 506(b)
▶$4.1MraisedMay 2018 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean CheeverDirector
- Ian ClementsDirector
- Chen Xiao-DongDirector
- Mark D HorseyExecutive Officer
- Robert HutchensDirector
- John W FeikDirector
- Paul CastellaDirector
- Steven DavisDirector
- Catherine BurzikDirector
- Robert S LangerDirector
- Offering amount
- $4.3M
- Amount sold
- $4.1M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapbio13 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Combined Therapeutics12 shared keywordsCombined Therapeutics Inc. (CTx) is a privately held biotechnology company developing mRNA vaccines and therapeutics using a proprietary multi-organ protection technology for tissue-specific mRNA expression. Its initial focus is on vaccines and vaccine adjuvants for infectious diseases and oncology.
Bionity12 shared keywordsBionity.com is a German-language B2B trade portal for the life sciences, biotechnology, and pharmaceutical industries, offering news, trends, supplier directories, job listings, and lab and production solutions. Operated by LUMITOS AG, it serves professionals in industry, research, and science and provides online marketing services to reach this B2B audience.
Companies competing with StemBioSys for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $143K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does StemBioSys do?
- StemBioSys develops cell culture technology, including the patented CELLvo Matrix that replicates the body's physiological microenvironment to expand mesenchymal stem cells and specialty cells while preserving their stem-like properties. It supplies cells and cell expansion tools for stem cell research and regenerative medicine applications.
- Who founded StemBioSys?
- StemBioSys was founded by Chen Xiao-Dong, Steven Davis, Xiao-Dong Chen.
- Who are StemBioSys's investors?
- StemBioSys's investors include Targeted Technology Funds.
- How much funding has StemBioSys raised?
- StemBioSys has disclosed $5.5M raised across 2 of its 4 known rounds.
- Where is StemBioSys headquartered?
- StemBioSys is headquartered in San Antonio, US.